. Author manuscript; available in PMC: 2020 Jan 1.

Published in final edited form as: Cancer Chemother Pharmacol. 2018 Oct 16;83(1):61–70. doi: 10.1007/s00280-018-3702-9

Table 4.

Univariate Analysis: Odds of high hormone/chemokine concentration among obese vs. non-obese patients enrolled on Cancer Survivorship Cohort by cancer type.

Mediator	Endometrial Cancer		Ovarian Cancer
Mediator	Odds Ratio (95% CI)	P-Value	Odds Ratio (95% CI)	P-Value
CCL2	1.70(0.45–6.36)	0.433	5.63 (0.75–42.36)	0.094
CCL5	0.89 (0.25–3.16)	0.855	1.40 (0.23–8.46)	0.714
Estrone	3.25 (0.87–12.13)	0.080	0.714 (0.12–4.32)	0.714
Estradiol	11.20 (2.51–50.08)	0.002	5.33 (0.78–36.33)	0.087
Testosterone	3.25 (0.87–12.13)	0.080	1.14 (0.18–7.23)	0.888
DHT	2.57 (0.71–9.36)	0.152	1.04 (0.18–6.12)	0.964

Odds ratio reference point equals 1.0

Concentration of hormone, chemokines were dichotomized at the median

^**

Univariable logistic regression model

^***

Endometrial cancer: obese group n=20, non-obese group n=19, Ovarian cancer: obese group n=13, non-obese group n=9